EU/3/18/2123

About

On 14 December 2018, orphan designation (EU/3/18/2123) was granted by the European Commission to IQVIA RDS Ireland Limited, Ireland, for 6,8-bis(benzylthio)octanoic acid (also known as CPI-613) for the treatment of acute myeloid leukaemia.

Key facts

Active substance
6,8-bis(benzylthio)octanoic acid
Disease / condition
Treatment of acute myeloid leukaemia
Date of decision
14/12/2018
Outcome
Positive
Orphan decision number
EU/3/18/2123

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

IQVIA RDS Ireland Limited
Estuary House
East Point Business Park
Fairview
Dublin 3
Ireland
Tel. +353 1 819 51 00
E-mail: kelly.theel@iqvia.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;

How useful was this page?

Add your rating